Loss of expression of Syndecan-1 is associated with Tumor Recurrence, Metastatic Potential, and Poor Survival in patients with Colorectal carcinoma
Open Access
- 20 November 2020
- journal article
- research article
- Published by Pakistan Journal of Medical Sciences in Pakistan Journal of Medical Sciences
- Vol. 37 (1) , 114-120
Abstract
Objective: The loss of expression of syndecansyndecan-1 is associated with poor prognosis in many types of human cancer. The objective of this study was to evaluate the relation between syndecan-1 immunoexpression and several clinicopathological parameters in a subset of colorectal carcinoma (CRC) patients. Methods: Pathology tissue blocks of 202 primary tumors, 41 adenomas, and 37 normal colonic mucosae were used in this study. The cases diagnosed in the period 1995–2015 was included in the study. Immunohistochemistry analysis was performed using anti-CD138/syndecan-1 (B-A38) mouse monoclonal antibody. A semiquantitative method was used to score the syndecan-1 expression based on an evaluation of the percentage and intensity of the membranous and cytoplasmic expression. The data collected from Pathology Department at King Abdulaziz University Hospital, Jeddah, Saudi Arabia. This is a retrospective cohort study that was conducted from July 2018 until August 2019. Results: Loss of syndecan-1 immunoexpression was observed in 72 (42.6%), 5 (12.2%), and 3 (8.1%) cases of CRC, adenomas, and normal mucosae, respectively. Low expression of syndecan-1 showed an association with nodal (p=0.003) and distant (p=0.001) metastasis, lymphovascular invasion (p=0.001), and tumor recurrence (p=0.006). Low syndecan-1 expression were associated with short overall survival (OS) (log rank 4.019, p=0.045) and disease-free survival (DFS) probabilities (log rank 4.748, p=0.029). Conclusion: Loss of syndecan-1 immunoexpression is associated with metastatic potential, tumor recurrence and shorter survival in CRC and is considered a potential biomarker of poor prognosis in CRC patients. doi: https://doi.org/10.12669/pjms.37.1.2592 How to cite this:Al-Maghrabi J. Loss of expression of Syndecan-1 is associated with Tumor Recurrence, Metastatic Potential, and Poor Survival in patients with Colorectal carcinoma. Pak J Med Sci. 2021;37(1):114-120. doi: https://doi.org/10.12669/pjms.37.1.2592 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Keywords
This publication has 25 references indexed in Scilit:
- A transmembrane C-terminal fragment of syndecan-1 is generated by the metalloproteinase ADAM17 and promotes lung epithelial tumor cell migration and lung metastasis formationCellular and Molecular Life Sciences, 2015
- Syndecan-1 Expression Is Associated with Tumor Size and EGFR Expression in Colorectal Carcinoma: A Clinicopathological Study of 230 CasesInternational Journal of Medical Sciences, 2015
- Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancerBritish Journal of Cancer, 2014
- Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinomaWorld Journal of Gastroenterology, 2012
- Prognostic significance of syndecan-1 expression in cervical cancersJournal of Gynecologic Oncology, 2011
- The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinomaJournal of Gynecologic Oncology, 2010
- The signaling mechanisms of syndecan heparan sulfate proteoglycansCurrent Opinion in Cell Biology, 2009
- Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinomaEuropean Journal of Gastroenterology & Hepatology, 2008
- Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: An immunohistochemical study of clinically annotated tumorsBMC Cancer, 2008
- Reduced Expression of Syndecan‐1 Affects Metastatic Potential and Clinical Outcome in Patients with Colorectal CancerJapanese Journal of Cancer Research, 2001